Berlin, A senior German immunologist, Carsten Watzl, has urged his country to change its mind and start allowing persons aged over 65 to receive the Oxford-AstraZeneca vaccine.
In a BBC interview, Watzl, head of the German Society for Immunology, predicted regulators would have to reverse their decision to not recommend the jab for older people.
He urged German Chancellor Angela Merkel to have the vaccine live on TV to prove it is safe.
Germany’s vaccine commission is currently reviewing its recommendation.
Watzl’s call comes after recent studies in Scotland showed the AstraZeneca jab to be effective among the elderly.
Germany is one of several EU states that have expressed doubts over the efficacy of the vaccine in older people.
The country is currently struggling to avoid a third wave of infections as cases remain stubbornly high.
The EU’s medical regulator approved the use of the Oxford-AstraZeneca vaccine for all age groups in January.
But the rollout was met by some public scepticism after regulators in countries including France, Germany and Italy recommended that it should not be used for people over 65. They citied insufficient data on its efficacy for older people.
German health authorities have so far used fewer than 300,000 of the 1.17 million doses of the AstraZeneca vaccine the country has received.
In January, French President Emmanuel Macron said the jab was “quasi-ineffective” for older age groups – a claim strongly refuted by the UK government and British medical regulators. AstraZeneca itself says the vaccine is effective at all ages.
The UK is among countries that have approved the jab for all age groups.
The decision was boosted by recent research led by Public Health Scotland, which found that four weeks after the first dose, hospital admissions were reduced by 85 per cent and 94 per cent for the Pfizer-BioNTech and AstraZeneca jabs respectively.
Among the over 80s, there was an overall 81 per cent reduction in the numbers admitted to hospital when the results for both vaccines were combined.
Leave a Reply